InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...
Company
ZAP-X Gyroscopic Radiosurgery Platform Receives NMPA Approval for Brain Tumor Treatment
US-based Zap Surgical Systems Inc. has announced that it has received market approval in China...
NMPA Approves Pitolisant for Narcolepsy-Related Excessive Daytime Drowsiness and Cataplexy
The National Medical Products Administration (NMPA) has approved pitolisant as a treatment for excessive daytime...
Ascentage Pharma’s Olverembatinib Gets NMPA Greenlight for Phase III Study in Ph+ ALL
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the National...
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Jacobio Pharma Retakes Global Rights to SHP2 Inhibitors After Terminating AbbVie Agreement
China-based Jacobio Pharma (HKG: 1167) has announced the cancellation of a licensing agreement with US...
Helio Genomics’ Sister Company LAMH Wins NMPA Approval for Liver Cancer Test in China
Helio Genomics has announced that its ‘sister company’ Laboratory for Advanced Medicine & Health Group...
Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development
Wuhan-based Binhui Biopharmaceutical and Hubei Topgene Biotechnology Co., Ltd have announced a strategic partnership to...
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd...
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public...
Shanghai’s Huangpu District Launches RMB Fund to Boost Fintech, AI, and Biotech Firms
The South China Morning Post reports that the local government in Shanghai’s Huangpu district has...
Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study
Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data...
Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round
Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised...
Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China
Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...
SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...
Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...
InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection
InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...
Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...